Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2289-2310

  Tsou, H R ^a   Liu, Xiaoxiang ^a   Birnberg, Gary ^a   Kaplan, Joshua ^a   Otteng, Mercy ^a   Tran, Tritin ^a   Kutterer, Kristina ^a   Tang, Zhilian ^a   Suayan, Ron ^a   Zask, Arie ^a   Ravi, Malini ^a   Bretz, Angela ^a   Grillo, Mary ^b   Mcginnis, John P ^b   Rabindran, Sridhar K ^b,c   Ayral Kaloustian, Semiramis ^a   Mansour, Tarek S ^a  

^a WYETH RESEARCH   (United States)

^b Oncology Research   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3,4 DIHYDROXYPHENYLAMINO)METHYLENE] 4H ISOQUINOLINE 1,3 DIONE; 4 (BENZYLAMINOMETHYLENE)ISOQUINOLINE 1,3(2H,4H) DIONE DERIVATIVE; 4 [(3 HYDROXY 4 PYRIDIN 2 YLBENZYLAMINO)METHYLENE] 6 IODO 4H ISOQUINOLINE 1,3 DIONE; 4 [(3 HYDROXY 4 PYRIDIN 3 YLBENZYLAMINO)METHYLENE] 6 IODO 4H ISOQUINOLINE 1,3 DIONE; 4 [(3 HYDROXY 4 PYRIDIN 4 YLBENZYLAMINO)METHYLENE] 6 IODO 4H ISOQUINOLINE 1,3 DIONE; 4 [(3,4 DIHYDROXYBENZYLAMINO)METHYLENE] 4H ISOQUINOLINE 1,3 DIONE; 4 [(4 FURAN 2 YL 3 HYDROXYBENZYLAMINO)METHYLENE] 6 IODO 4H ISOQUINOLINE 1,3 DIONE; 4 [(4 FURAN 3 YL 3 HYDROXYBENZYLAMINO)METHYLENE] 6 IODO 4H ISOQUINOLINE 1,3 DIONE; 4 [(PYRIDYLMETHYL)AMINOMETHYLENE]ISOQUINOLINE 1,3(2H,4H) DIONE DERIVATIVE; 4 [[(2 HYDROXYBIPHENYL 4 YLMETHYL)AMINO]METHYLENE] 6 IODO 4H ISOQUINOLINE 1,3 DIONE; 4 [[(3 HYDROXY 4 METHOXYBENZYL)AMINO]METHYLENE]ISOQUINOLINE 1,3(2H,4H) DIONE; 4 [[(3 HYDROXY 4 PROPOXYBENZYL)AMINO]METHYLENE] 6 IODOISOQUINOLINE 1,3(2H,4H) DIONE; 4 [[(3 HYDROXYBENZYL)AMINO]METHYLENE]ISOQUINOLINE 1,3(2H,4H) DIONE; 4 [[(4 HYDROXY 5 PROPOXYPYRIDIN 2 YLMETHYL)AMINO]METHYLENE] 6 IODO 4H ISOQUINOLINE 1,3 DIONE; 4 [[(4 HYDROXYBENZYL)AMINO]METHYLENE]ISOQUINOLINE 1,3(2H,4H)DIONE; 4 [[(4 METHYL 3 HYDROXYBENZYL)AMINO]METHYLENE] 6 IODOISOQUINOLINE 1,3(2H,4H) DIONE; 4 [[[1 (3 FURYL) 2 OXO 1,2 DIHYDROPYRIDIN 4 YL]METHYL]AMINO]METHYLENE 6 IODOISOQUINOLINE 1,3(2H,4H) DIONE; 6 CYCLOPENTYL 4 [[(4 HYDROXY 5 PROPOXYPYRIDIN 2 YLMETHYL)AMINO]METHYLENE] 4H ISOQUINOLINE 1,3 DIONE; 6 CYCLOPENTYL 4 [[(5 FURAN 3 YL 4 HYDROXYPYRIDIN 2 YLMETHYL)AMINO]METHYLENE] 4H ISOQUINOLINE 1,3 DIONE; 6 IODO 4 [[(3 HYDROXY 4 METHOXYBENZYL)AMINO]METHYLENE]ISOQUINOLINE 1,3(2H,4H) DIONE; 6 IODO 4 [[(4 HYDROXY 5 METHOXYPYRIDIN 2 YLMETHYL)AMINO]METHYLENE] 4H ISOQUINOLINE 1,3 DIONE; 6 TERT BUTYL 4 [[(4 HYDROXY 5 PHENYLPYRIDIN 2 YLMETHYL)AMINO]METHYLENE]4H ISOQUINOLINE 1,3 DIONE; 6 TERT BUTYL 4 [[(4 HYDROXY 5 PROPOXYPYRIDIN 2 YLMETHYL)AMINO]METHYLENE] 4H ISOQUINOLINE 1,3 DIONE; 6 TERT BUTYL 4 [[(5 FURAN 3 YL 4 HYDROXYPYRIDIN 2 YLMETHYL)AMINO]METHYLENE] 4H ISOQUINOLINE 1,3 DIONE; [[(5 FURAN 3 YL 4 HYDROXYPYRIDIN 2 YLMETHYL)AMINO]METHYLENE] 6 IODO 4H ISOQUINOLINE 1,3 DIONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; MOLECULAR MODEL; NONHUMAN; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TECHNIQUE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROGEN BONDING; ISOQUINOLINES; MICROSOMES, LIVER; MODELS, MOLECULAR; PHOSPHORYLATION; PYRIDINES; RATS; RETINOBLASTOMA PROTEIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65449126280     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801026e     Document Type: Article

References (55)

1. Massague, J. G1 cell cycle and cancer. Nature 2004, 432, 298-306.
2. Sherr, C. J.; Roberts, J. M. CDK inhibitors: Positive and negative regulators of G1 progression. Genes Dev. 1999, 13, 1501-1512.
3. Harbour, J. W.; Luo, R. X.; Dei Santi, A.; Postigo, A. A.; Dean, D. C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999, 98, 859-869.
4. Dyson, N. The regulation of E2F by pRB -family proteins. GeneDev. 1998, 12, 2245-2262.
5. Hanahan, D.; Weiberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
6. Hall, M.; Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv. Cancer Res. 1996, 68, 67-108.
7. Michalides, R. J. A. M. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J. Clin. Pathol. 1999, 52, 555-568.
8. Grillo, M.; Bott, M. J.; Khandke, N.; McGinnis, J. P.; Miranda, M.; Meyyappan, M.; Rosfjord, E. C; Rabindran, S. K. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res. Treat. 2006, 95, 185-194.
9. Tam, S. W.; Theodoras, A. M.; Shay, J. W.; Draetta, G. F.; Pagano, M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene 1994, 9, 2663-2674.
10. Arber, N.; Doki, Y.; Han, E. K.-H.; Sgambato, A.; Zhou, P.; Kim, N.-H.; Delohery, T.; Klein, M. G.; Holt, P. R.; Weinstein, I. B. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 1997, 57, 1569-1574.
11. Bartkova, J.; Lukas, J.; Muller, H.; Lutzhoft, D.; Strauss, M.; Bartek, K. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 1994, 57, 353-361.
12. Uto, H.; Ido, A.; Moriuchi, A.; Onaga, Y.; Nagata, K.; Onaga, M.; Tahara, Y.; Hori, T.; Hirono, S.; Hayashi, K.; Tsubouchi, H. Transduction of antisense cyclin D1 using two-step gene transfer inhibits the growth of rat hepatoma cells. Cancer Res. 2001, 61, 4779-4783.
13. Yu, Q.; Geng, Y.; Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411, 1017-1021.
14. Yu, Q.; Sicinska, E.; Geng, Y.; Ahnstrom, M.; Zagozdzon, A.; Kong, Y.; Gardner, H.; Kiyokawa, H.; Harris, L. N.; Stal, O.; Sicinski, P. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006, 9, 23-32.
15. Landis, M. W.; Pawlyk, B. S.; Li, T.; Sicinski, P.; Hinds, P. W. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006, 9, 13-22.
16. (16)
17. (a) Malumbres, M.; Pevarello, P.; Barbacid, M.; Bischoff, J. R. CDK inhibitors in cancer therapy: What is next. Trends Pharmacol. Sci. 2007, 29, 16-21.
18. (b) Byrdt, J. C; Thomas S. Lin, T. S.; Dalton, J. T.; Wu, D.; Phelps, M. A.; Fischer, B.; Moran, M.; Blum, K. A.; Rovin, B.; Brooker-McEldowney, M.; Broering, S.; Schaaf, L. J.; Johnson, A. J.; Lucas, D. M.; Heerema, N. A.; Lozanski, G.; Young, D. C; Suarez, J.-R.; Colevas, A. D.; Grever, M. R. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109, 399-404.
19. Fry, D. W.; Harvey, P. J.; Keller, P. R. Specific inhibition of cyclin-dependent kinase 4/6 by PD0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3, 1427-1438.
20. Kubo, A.; Nakagawa, K.; Varma, R. K.; Conrad, N. K.; Cheng, J. Q.; lee, W.-C; Testa, J. R.; Johnson, B. E.; Kaye, F. E.; Kelley, M. J. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin. Cancer Res. 1999, 5, 4279-4286.
21. Soni, R.; O'Reilly, T.; Furet, P.; Muller, L.; Stephan, C; Zumstein-Mecker, S.; Fretz, H.; Fabbro, D.; Chaudhuri, B. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Ins. 2001, 93, 436-446.
22. Ikuta, M.; Kamata, K.; Fukasawa, K.; Honma, T.; Machida, T.; Hirai, H.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S. Crystallographic approcach to identification of cyclin-dependent kinase 4 (CDK4) -specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem. 2001, 276, 27548-27554.
23. Grell, W.; Walter, R.; Heckel, A.; Himmelsbach, F.; Wittneben, H.; van Meel, J.; Redemann, N; Haigh, R. Preparation of 3- (α-Heteroary- laminobenzylidene) -2-indolinones as Cyclin Dependent Kinase Inhibitors. DE 19815020 A1 19991007, 1999.
24. Tsou, H. R.; Otteng, M.; Tran, T.; Floyd, M. B.; Reich, M.; Birnberg, G; Kutterer, K.; Ayral-Kaloustian, S.; Ravi, M.; Nilakantan, R.; Grillo, M.; McGinnis, J. P.; Rabindran, S. K. 4- (Phenylaminomethylene) iso-quinoline-1, 3 (2H, 4H) -diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4). J. Med. Chem. 2008, 51, 3507-3525.
25. De Lombaert, S.; Fink, C. A.; Firoozina, F.; Hoyer, D. W. Certain Thiol inhibitors of Endothelin-Converting Enzyme. PCT Int. Appl. WO 9955726 A1 19991104, 1999.
26. (a) Sagi, K.; Nakagawa, T.; Yamanashi, M.; Makino, S.; Takahashi, M.; Takayanagi, M.; Takenaka, K.; Suzuki, N.; Ono, S.; Kataoka, N.; Ishikawa, K.; Shima, S.; Fukuda, Y.; Kayahara, T.; Takehana, S.; Shima, Y.; Tashiro, K.; Yamamoto, H.; Yoshimoto, R.; Iwata, S.; Tsuji, T.; Sakurai, K.; Shoji, M. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-Substituted-4-amidinophenyl) pyruvic and -propionic acid. J. Med. Chem. 2003, 46, 1845-1857. (b) Imanishi, N.; Iwaoka, K.; Koshio, H.; Nagashima, S.-y.; Kazuta, K.-i.; Ohta, M.; Sakamoto, S.; Ito, H.; Akuzawa, S.; Kiso, T.; Tsukamoto, S.-i.; Mase, T. New thiazole derivatives as potent and selective 5-hydroxytriptamine 3 (5-HT3) receptor agonists for the treatment of constipation. Bioorg. Med. Chem. 2003, 11, 1493-1502.
27. Singh, B.; Lesher, G. Y. Synthesis of aza analogs of Amrinone. Hereocycles 1990, 31, 2163-2172.
28. Brown, T. H.; Blakemore, R. C; Durant, G. J.; Ganellin, C. R.; Parsons, M. E.; Rasmussen, A. C., zprint; DA]; Rawlings, D. A. Isocytosine H2-receptor histamine antagonists. IV. The synthesis and biological activity of donetidine (SK&F 93574) and related compounds. Eur. J. Med. Chem. 1993, 28, 601-608.
29. Walpole, C. S. J.; Wrigglesworth, R.; Bevan, S.; Campbell, E. A.; Dray, A.; James, I. F.; Perkins, M. N.; Reid, D. J.; Winter, J. Analogs of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region". J. Med. Chem. 1993, 36 (16), 2362-2372.
30. Sugahara, M.; Ukita, T. A facile copper-catalyzed Ullmann condensation: N-Arylation of heterocyclic compounds containing an -NHCO-moiety. Chem. Pharm. Bull. 1997, 45 (4), 719-721.
31. Campbell, K. N; Ackerman, J. F.; Campbell, B. K. Studies on g-Pyrones. I. Derivatives of Kojic Acid. J. Org. Chem. 1950, 15, 221-6.
32. Cizmaricova, Ruzena; Miskikova, E.; Gregan, F. Derivatives of kojic acid. Pharmazie. 1991, 46 (6), 460.
33. Kamino, T.; Kuramochi, K.; Kobayashi, S. A concise approach to 5-substituted-4-pyrones from kojic acid. Tet. Lett. 2003, 44, 7349-7351.
34. Wishka, D. G.; Graber, D. R.; Seest, E. P.; Dolak, L. A.; Han, F.; William Watt, W.; Joel Morris, J. Stereoselective synthesis of furo[2, 3-c]pyridine pyrimidine thioethers, a new class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. J. Org. Chem. 1998, 63 (22), 7851-7859.
35. Nightingale, D.; Janes, J. R. The Alkylation of o- and p-Xylene. J. Amer. Chem. Soc. 1944, 66, 154-155.
36. (a) Markwalder, J. A.; Arnone, M. R.; Benfield, P. A.; Boisclair, M.; Burton, C. R.; Chang, C.-H.; Cox, S. S.; Czerniak, P. M.; Dean, C. L.; Doleniak, D.; Grafstrom, R.; Harrison, B. A.; Kaltenbach, III, R. F.; Nugiel, D. A.; Rossi, K. A.; Sherk, S. R.; Sisk, L. M.; Stouten, P.; Trainor, G. L.; Worland, P.; Seitz, S. P. Synthesis and biological evaluation of 1-aryl-4, 5-dihydro-1H-pyrazolo[3, 4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2004, 47, 5894- 5911.
37. (b) Rossi, K. A.; Markwalder, J. A.; Seitz, S. P.; Chang, C.-H.; Cox, S.; Boisclair, M. D.; Brizuela, L.; Brenner, S. L.; Stouten, P. F. W. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyra-zolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. J. Comput.-Aided Mol. Des. 2005, 19, 111-122.
38. (c) Shangari, N.; Chan, T. S.; O'Brien, P. J. Sulfation and glucuronidation of phenols: Implications in coenyzme Q metabolism. Methods Enzymol. 2005, 400, 342-259.
39. Kim, K. H. Quantitative structure-activity relationships of the metabolism of drugs by uridine diphosphate glucuronosyltransferase. J. Phamacol. Sci. 1991, 80 (10), 966-970.
40. Yin, H.; Bennett, G.; Jones, J. P. Mechanistic studies of uridine diphosphate glucuronosyltransferase. Chem.-Biol. Interact. 1994, 90, 47-58.
41. (a) Katritzky, A. R.; Lagowski, J. M. Prototropic tautomerism of heteroaromatic compounds: I. General discussion and methods of study. Adv. Heterocyclic Chem. 1963, 1, 311-38.
42. (b) Wang, J.; Boyd, R. J. Tautomeric equilibria of hydroxypyridines in different solvents: An ab initio study. J. Phys. Chem. 1996, 100, 16141-16146.
43. De Kowaleski, D. G.; Contreras, R. H.; diez, E.; Esteban, A. NMR J (C, C) scalar coupling analysis of the effects of substituents on the keto-enol tautomeric equilibrium in 2-OH-n-X-pyridines. An experimental and DFT study. Mol. Phys. 2004, 23-24, 2607-2615.
44. GLIDE; Schrodinger Software: Portland, OR (www.schrodinger.com).
45. (a) Thompson, S. K.; Murthy, K. H. M.; Zhao, B.; Winborne, E.; Green, D. W.; Fisher, S. M.; DesJarlais, R. L.; Thomszek, T. A., Jr.; Meek, T. D.; Gleason, J. G.; Abdel-Meguid, S. S. Rational design, syntheis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'-P2' amide bond isostere. J. Med. Chem. 1994, 37, 3100-3107.
46. A and a histidine side chain in photosystem II as revealed by fourier transform infrared spectroscopy. Biochemistry 1999, 38, 399-403.
47. (c) Edgcomb, S. P.; Murphy, K. P. Variability in the pKa of histidine side-chains correlates with burial within proteins. Proteins: Struct., Funct., Bioinf. 2002, 49, 1-6.
48. McInnes, C; Wang, S.; Anderson, S.; O'Boyle, J.; Jackson, W.; Kontopidis, G.; Meades, C; Mezna, M.; Thomas, M.; Wood, G; Lane, D. P.; Fischer, P. M. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem. Biol. 2004, 11, 525-534.
49. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Iduta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-based generation of a new class of potent cdk4 inhibitors: New de novo design strategy and library design. J. Med. Chem. 2001, 44, 4615-4627.
50. Aubry, C.; Wilson, A. J.; Jenkins, P. R.; Mahale, S.; Chaudhuri, B.; Marechal, J.; Sutcliffe, M. J. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin. Org. Biomol. Chem. 2006, 4, 787-801.
51. Pratt, D. J.; Bentley, J.; Jewsbury, F.; Boyle, T.; Endicott, J. A.; Noble, M. E. M. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J. Med. Chem. 2006, 49, 5470-5477.
52. Park, H.; Yeom, M. S.; Lee, S. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: Comparative molecular dynamics simulation studies of CDK2 and CDK4. ChemBioChem. 2004, 5, 1662-1672.
53. SYBYL, version 7.2; Tripos, Inc.: St. Louis, MO, 2006.
54. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
55. Jorgensen, W. L.; Maxwell, D. S.; Triado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118 (45), 11225-11236.